Kintara Therapeutics (KTRA) Short Interest Ratio & Short Volume → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free KTRA Stock Alerts $0.31 -0.01 (-3.12%) (As of 05/31/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Kintara Therapeutics Short Interest DataCurrent Short Interest1,130,000 sharesPrevious Short Interest4,040,000 sharesChange Vs. Previous Month-72.03%Dollar Volume Sold Short$148,143.00Short Interest Ratio0.1 Days to CoverLast Record DateMay 15, 2024Outstanding Shares55,310,000 sharesPercentage of Shares Shorted2.04%Today's Trading Volume25,961,219 sharesAverage Trading Volume17,281,048 sharesToday's Volume Vs. Average150% Short Selling Kintara Therapeutics ? Sign up to receive the latest short interest report for Kintara Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartKTRA Short Interest Over TimeKTRA Days to Cover Over TimeKTRA Percentage of Float Shorted Over Time Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. Kintara Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/20241,130,000 shares $148,143.00 -72.0%N/A0.1 $0.13 4/30/20244,040,000 shares $627,412.00 +477.1%N/A0.3 $0.16 4/15/2024700,000 shares $77,070.00 +6.2%N/A0.1 $0.11 3/31/2024658,900 shares $68,525.60 -70.1%N/A0 $0.10 3/15/20242,200,000 shares $207,020.00 +0.5%N/A0.2 $0.09 2/29/20242,190,000 shares $234,330.00 +432.7%N/A0.2 $0.11 Get the Latest News and Ratings for KTRA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Kintara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/2024411,100 shares $44,028.81 +150.7%N/A0 $0.11 1/31/2024164,000 shares $23,747.20 -59.7%5.0%0 $0.14 1/15/2024407,100 shares $56,953.29 +234.8%12.3%0.1 $0.14 12/31/2023121,600 shares $20,623.36 -60.4%3.7%0 $0.17 12/15/2023306,900 shares $60,766.20 -12.8%9.3%0.3 $0.20 11/30/2023352,000 shares $119,680.00 -34.6%10.9%0.5 $0.34 11/15/2023538,500 shares $189,228.90 +541.8%32.3%1.3 $0.35 10/31/202383,900 shares $62,664.91 +126.2%5.0%0.6 $0.75 10/15/202337,100 shares $127,253.00 +152.4%2.2%2.1 $3.43 9/30/202314,700 shares $59,388.00 +53.1%0.9%0.9 $4.04 9/15/20239,600 shares $39,936.00 -66.6%0.6%0.1 $4.16 8/31/202328,700 shares $130,585.00 +38.0%1.8%0.2 $4.55 8/15/202320,800 shares $68,640.00 -23.3%1.2%0.1 $3.30 7/31/202327,100 shares $120,866.00 -46.6%1.6%0.2 $4.46 7/15/202350,700 shares $235,248.00 -9.8%3.1%0.3 $4.64 6/30/202356,200 shares $226,486.00 +200.5%3.4%0.3 $4.03 6/15/202318,700 shares $70,125.00 -26.4%1.1%0.5 $3.75 5/31/202325,400 shares $81,534.00 +75.2%1.5%0.6 $3.21 5/15/202314,500 shares $43,500.00 +12.4%0.9%0.3 $3.00 4/30/202312,900 shares $35,733.00 -41.9%0.8%0.3 $2.77 4/15/202322,200 shares $63,025.80 -12.9%1.4%0.9 $2.84 3/31/202325,500 shares $89,989.50 +390.4%1.6%0.9 $3.53 3/15/20235,200 shares $17,108.00 -85.4%0.3%0.1 $3.29 2/28/202335,600 shares $177,644.00 +65.6%2.2%0.5 $4.99 2/15/202321,500 shares $130,075.00 +9.7%1.3%0.1 $6.05 1/31/202319,600 shares $123,480.00 -14.4%1.2%0.1 $6.30 1/15/202322,900 shares $162,819.00 -42.2%1.5%0.1 $7.11 12/30/202239,600 shares $272,844.00 -56.3%2.7%0.1 $6.89 12/15/202290,600 shares $834,426.00 -75.7%N/A0.2 $9.21 11/30/2022373,400 shares $2.50 million +614.0%N/A1 $6.70 11/15/202252,300 shares $208,154.00 -97.4%N/A0.9 $3.98 10/31/20222,040,000 shares $219,708.00 +196.3%N/A0.9 $0.11 10/15/2022688,400 shares $65,535.68 -16.8%N/A0.2 $0.10 9/30/2022827,000 shares $89,316.00 +2.2%N/A0.3 $0.11The only AI company to buy (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. 9/15/2022808,900 shares $128,210.65 -11.3%N/A0.3 $0.16 8/31/2022911,400 shares $141,358.14 -31.0%N/A0.3 $0.16 8/15/20221,320,000 shares $245,784.00 +686.7%N/A0.4 $0.19 7/31/2022167,800 shares $31,730.98 -56.4%N/A0 $0.19 7/15/2022384,500 shares $94,548.55 -65.1%N/A0.1 $0.25 6/30/20221,100,000 shares $305,800.00 +158.5%N/A0.3 $0.28 6/15/2022425,500 shares $99,439.35 -35.1%N/A0.1 $0.23 5/31/2022655,700 shares $118,026.00 +42.1%N/A0.2 $0.18 5/15/2022461,600 shares $86,780.80 -64.5%N/A0.2 $0.19 4/30/20221,300,000 shares $377,000.00 +157.6%N/A0.7 $0.29 4/15/2022504,700 shares $160,999.30 +76.7%N/A0.4 $0.32 3/31/2022285,600 shares $113,640.24 -17.5%N/A0.3 $0.40 3/15/2022346,300 shares $107,353.00 +33.5%N/A0.7 $0.31 2/28/2022259,400 shares $94,706.94 -59.0%N/A0.5 $0.37 2/15/2022633,000 shares $294,978.00 -25.4%N/A1 $0.47 1/31/2022849,000 shares $352,335.00 -5.2%N/A1.2 $0.42 1/15/2022895,100 shares $428,752.90 +15.6%N/A0.9 $0.48 12/31/2021774,500 shares $394,995.00 -14.3%N/A0.5 $0.51 12/15/2021903,500 shares $575,529.50 -15.6%N/A0.4 $0.64 11/30/20211,070,000 shares $749,000.00 +33.8%N/A0.5 $0.70 11/15/2021799,600 shares $699,650.00 +148.9%N/A0.4 $0.88 10/29/2021321,300 shares $280,494.90 -64.6%N/A0.2 $0.87 10/15/2021907,100 shares $784,641.50 +24.2%N/A0.6 $0.87 9/30/2021730,500 shares $628,376.10 -30.4%N/A0.8 $0.86 9/15/20211,050,000 shares $1.41 million -14.6%3.9%1.3 $1.34 8/31/20211,230,000 shares $1.87 million -1.6%4.5%1.8 $1.52 8/13/20211,250,000 shares $1.94 million -2.3%4.6%1 $1.55 7/30/20211,280,000 shares $1.97 million -21.0%4.7%1 $1.54 7/15/20211,620,000 shares $2.61 million +22.7%5.9%1.3 $1.61 6/30/20211,320,000 shares $3.00 million +13.8%4.8%1 $2.27 6/15/20211,160,000 shares $2.12 million -35.2%4.3%1.4 $1.83 5/28/20211,790,000 shares $2.88 million +506.0%6.6%2.2 $1.61 5/14/2021295,400 shares $384,020.00 -43.7%1.1%0.9 $1.30 4/30/2021524,300 shares $718,291.00 -15.8%2.0%0.7 $1.37 4/15/2021622,600 shares $1.00 million +1.5%2.5%0.6 $1.61 3/31/2021613,300 shares $1.09 million -32.9%2.5%0.6 $1.77 3/15/2021914,600 shares $1.97 million +4.7%3.7%0.8 $2.15 2/26/2021873,600 shares $1.73 million -4.6%3.7%0.8 $1.98 2/12/2021915,700 shares $2.36 million +53.4%3.9%0.8 $2.58 1/29/2021597,000 shares $1.13 million +285.4%3.3%0.7 $1.90 1/15/2021154,900 shares $215,311.00 No Change0.9%0.3 $1.39 8/31/2020434,400 shares $582,096.00 +32.4%N/A0.4 $1.34 8/14/2020328,000 shares $380,480.00 +33.0%N/A0.3 $1.16 7/31/2020246,600 shares $234,270.00 +55.7%N/A0.2 $0.95 7/15/2020158,400 shares $107,712.00 -25.2%N/A0.2 $0.68 6/30/2020211,700 shares $142,918.67 -53.8%N/A0.3 $0.68 6/15/2020458,100 shares $508,491.00 +14.7%N/A0.8 $1.11 5/29/2020399,400 shares $411,382.00 +20.3%N/A1 $1.03 5/15/2020332,000 shares $209,359.20 +7.1%N/A1.2 $0.63 4/30/2020310,000 shares $169,663.00 -10.2%N/A1.6 $0.55The only AI company to buy (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. 4/15/2020345,100 shares $176,760.22 +7.6%N/A1.8 $0.51 3/31/2020320,700 shares $127,702.74 +2.6%N/A1.6 $0.40 3/13/2020312,600 shares $136,762.50 +6.0%N/A2.6 $0.44 2/28/2020295,000 shares $141,954.00 -0.2%N/A1.3 $0.48 2/14/2020295,600 shares $162,580.00 +11.2%N/A0.7 $0.55 1/31/2020265,800 shares $142,335.90 -31.1%N/A0.5 $0.54 1/15/2020385,600 shares $227,504.00 -31.1%N/A0.6 $0.59 12/31/2019559,900 shares $386,331.00 +18.2%N/A0.9 $0.69 11/29/2019531,400 shares $387,922.00 +60.7%21.8%0.9 $0.73 KTRA Short Interest - Frequently Asked Questions What is Kintara Therapeutics' current short interest? Short interest is the volume of Kintara Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 1,130,000 shares of KTRA short. Learn More on Kintara Therapeutics' current short interest. Is Kintara Therapeutics' short interest increasing or decreasing? Kintara Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 1,130,000 shares, a decrease of 72.0% from the previous total of 4,040,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Kintara Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Kintara Therapeutics: Daré Bioscience, Inc. (0.53%), NRx Pharmaceuticals, Inc. (7.00%), Acurx Pharmaceuticals, Inc. (4.43%), Reviva Pharmaceuticals Holdings, Inc. (6.38%), DURECT Co. (3.13%), VYNE Therapeutics Inc. (0.46%), Eyenovia, Inc. (10.27%), Cara Therapeutics, Inc. (5.23%), Lipocine Inc. (3.10%), Fortress Biotech, Inc. (11.49%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Kintara Therapeutics stock? Short selling KTRA is an investing strategy that aims to generate trading profit from Kintara Therapeutics as its price is falling. KTRA shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Kintara Therapeutics? A short squeeze for Kintara Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of KTRA, which in turn drives the price of the stock up even further. How often is Kintara Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KTRA, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: DARE Short Interest NRXP Short Interest ACXP Short Interest RVPH Short Interest DRRX Short Interest VYNE Short Interest EYEN Short Interest CARA Short Interest LPCN Short Interest FBIO Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:KTRA) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kintara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.